CD37 in B Cell Derived Tumors—More than Just a Docking Point for Monoclonal Antibodies

International Journal of Molecular Sciences

Matylda Kubacz¹  Malgorzata Bobrowicz¹  Magdalena Winiarska¹  Aleksander Slusarczyk¹ 

[1] Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland;

关键词: CD37;    tetraspanin;    non-Hodgkin lymphoma;    chronic lymphocytic leukemia;    immunotherapy;    monoclonal antibodies;   

DOI  :  10.3390/ijms21249531

来源: DOAJ

【 摘 要 】

CD37 is a tetraspanin expressed prominently on the surface of B cells. It is an attractive molecular target exploited in the immunotherapy of B cell-derived lymphomas and leukemia. Currently, several monoclonal antibodies targeting CD37 as well as chimeric antigen receptor-based immunotherapies are being developed and investigated in clinical trials. Given the unique role of CD37 in the biology of B cells, it seems that CD37 constitutes more than a docking point for monoclonal antibodies, and targeting this molecule may provide additional benefit to relapsed or refractory patients. In this review, we aimed to provide an extensive overview of the function of CD37 in B cell malignancies, providing a comprehensive view of recent therapeutic advances targeting CD37 and delineating future perspectives.

【 授权许可】

Unknown